Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
Open Access
- 22 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 394 (12), 2363-2379
- https://doi.org/10.1007/s00210-021-02149-4
Abstract
Chronic kidney diseaQueryse (CKD) is associated with oxidative stress which can interrupt the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling and decrease cyclic guanosine monophosphate (cGMP) production. Low cGMP concentrations can cause kidney damage and progression of CKD. The novel sGC activator runcaciguat targets the oxidized and heme-free form of sGC, restoring cGMP production under oxidative stress. The purpose of this study is to investigate if runcaciguat could provide an effective treatment for CKD. Runcaciguat was used for the treatment not only in rat CKD models with different etiologies and comorbidities, namely of hypertensive rats, the renin transgenic (RenTG) rat, and angiotensin-supplemented (ANG-SD) rat, but also in rats with diabetic and metabolic CKD, the Zucker diabetic fatty (ZDF) rat. The treatment duration was 2 to 42 weeks and runcaciguat was applied orally in doses from 1 to 10 mg/kg/bid. In these different rat CKD models, runcaciguat significantly reduced proteinuria (urinary protein to creatinine ratio; uPCR). These effects were also significant at doses which did not or only moderately decrease systemic blood pressure. Moreover, runcaciguat significantly decreased kidney injury biomarkers and attenuated morphological kidney damages. In RenTG rats, runcaciguat improved survival rates and markers of heart injury. These data demonstrate that the sGC activator runcaciguat exhibits cardio-renal protection at doses which did not reduce blood pressure and was effective in hypertensive as well as diabetic and metabolic CKD models. These data, therefore, suggest that runcaciguat, with its specific mode of action, represents an efficient treatment approach for CKD and associated CV diseases. Graphical abstractKeywords
This publication has 31 references indexed in Scilit:
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015
- Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidenceCurrent Opinion in Pharmacology, 2015
- The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and ActivatorsAngewandte Chemie, 2013
- Diabetes in Zucker Diabetic Fatty RatPublished by Springer Science and Business Media LLC ,2012
- Soluble guanylate cyclase: a potential therapeutic target for heart failureHeart Failure Reviews, 2012
- Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfideAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseJournal of the American College of Cardiology, 2011
- Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndromeJCI Insight, 2006
- Transgenic rats: new animal models in hypertension research. Invited lecture.Hypertension, 1991
- Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 geneNature, 1990